Transitioning to Pegylated Interferon for the Treatment of Cutaneous T-Cell Lymphoma: Meeting the Challenge of Therapy Discontinuation and a Proposed Algorithm

Table 2

Patient demographics, clinical features, and outcomes.

Patient	Age at diagnosis	Pathology diagnosis	Stage	IFN dose/week (MU)	TTNT-IFN (months)†	PEG-IFN start dose/week (ug)	Concurrent therapies‡	mSWAT (baseline)	SkinDex-29 (baseline)	PEG-IFN current dose	Adverse effects	Next line of treatment	TTNT–PEG-IFN (days) §	Time on PEG-IFN (months)¶	mSWAT	SkinDex-29	Outcome	OS from diagnosis (years)
1	50	SS	IVB	6	8	90	ECP	84	72	—		Moga	24	0.8	80	62	Alive	1.2
2	66	SS	IVB	6	7	90	ECP, retinoids	90	116	—		Moga	37	1.2	90	116	Alive	1.0
3	60	MF, LCT	IIB	6	38	90	UVB, carmustine	3	59	70	Decreased mood	—	—	6	20	61	Alive	9.6
4	69	MF (folliculotropic)	IIB	4.5	19	90	Acitretin, imiquimod, TCS	12	55	90		—	—	5	11	35	Alive	2.4
5	73	MF	IIB	9	21	90	UVB	80	52	—		Romi	128	4.3	60	76	Alive	13.6
6	67	MF, LCT	IIB	6	8	90	Isotretinoin	53.5	71	90		TSEB¶¶	—	5	26		Alive	5.4
7	86	MF, LCT	IIB	9	5	90	—	34	36	45	Grade 1 anemia	—	—	6	23	34	Alive	22.7
8	71	MF	IIIA	6	57	45	ECP, alitretinoin	NR	NR	45		—	—	5	27		Alive	7.9

†TTNT between interferon and pegylated interferon, ‡concurrent therapies during both IFN and PEG-IFN, § TTNT between pegylated interferon and the next line of treatment, if applicable, ¶ as of time of the publication, ¶¶ the patient was initiated on TSEB while remaining on PEG-IFN, initiated after 36 days on PEG-IFN. OS, overall survival; Moga, mogamulizumab; Romi, romidepsin; TSEB, total skin electron beam therapy; NR, not recorded